Igenica is harnessing the natural tumor microenvironment to deliver a pipeline of high-impact antibody-based cancer therapeutics.
The iTAb (in vivo anti-Tumor Antibody) technology is a proprietary platform for the generation of novel antibodies with therapeutic potential. The technology was invented in the laboratory of our co-founder, Robert Schreiber at Washington University in St. Louis, and further developed and refined at Igenica. Key attributes of the system are the cell based immunization strategy combined with generation of the humoral (antibody) response in the context of the tumor microenvironment. iTAb begins by employing proprietary highly characterized tumor cell lines transfected with human cancer target antigens of interest. The targets can be proteins containing a single transmembrane domain or very complex cancer antigens with multiple membrane-spanning domains that often are found to be intractable by other antibody generation methods. The modified tumor cells are implanted into syngeneic mice that have been pre-treated to disable their cellular immune responses. The mouse immune system, now biased towards antibody generation to fight the tumor, mounts a response highly focussed on the human cancer target of interest presented on the tumor cells. In addition to generating a highly diverse antibody repertoire to the antigen in its natural conformation, the methodology also serves as an in vivo screen for antibodies that manifest potent anti-tumor activities. These anti-tumor activities often result in tumor growth delay or even tumor rejection. Igenica has developed iTAb to provide a rapid murine antibody response to a selected human tumor antigen and generate disease-relevant monoclonal antibodies to cancer antigens. These antibodies provide the backbone of our high-impact antibody-based cancer therapeutics.